EA3231 A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em
- Phase III
- Trial Category: Head and Neck
Contact(s)
Mary Beth Wilwerding, RN Admin@NEcancertrials.com
Location(s)
Available at Nebraska Methodist Estabrook Cancer Center
Interested in More Information?
Please fill out the form below. Someone will get back to you as soon as possible.
"*" indicates required fields